Literature DB >> 20227987

Linezolid penetration into cerebrospinal fluid and brain tissue.

A Tsona1, S Metallidis, N Foroglou, P Selviaridis, T Chrysanthidis, G Lazaraki, M Papaioannou, J Nikolaidis, P Nikolaidis.   

Abstract

The aim of the study was to evaluate the penetration of linezolid into cerebrospinal fluid (CSF) and brain tissue after a single i.v. dose of 600 mg. The penetration of linezolid into cerebrospinal fluid and brain tissue was studied in 18 patients undergoing a neurosurgical procedure. Linezolid 600 mg i.v. was given with the induction of anesthesia. Mean concentrations of linezolid 2h after the final dose, in serum, cerbrospinal fluid and brain tissue were assayed by HPLC. CSF/serum and brain/serum ratios were 69.57% and 44.66% respectively. Concentrations of linezolid were above the MIC(90s )for staphylococci and streptococci. The concentrations obtained indicate good penetration of linezolid into CSF and brain tissue and support its use in the management of multidrug-resistant Gram-positive CNS infections.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20227987     DOI: 10.1179/joc.2010.22.1.17

Source DB:  PubMed          Journal:  J Chemother        ISSN: 1120-009X            Impact factor:   1.714


  8 in total

1.  Neuroprotective potential of Linezolid: a quantitative and distribution study via mass spectrometry.

Authors:  Sooraj Baijnath; Adeola Shobo; Linda A Bester; Sanil D Singh; Gert Kruger; Per I Arvidsson; Tricia Naicker; Thavendran Govender
Journal:  J Mol Histol       Date:  2016-06-21       Impact factor: 2.611

2.  Long term outcomes of patients with tuberculous meningitis: The impact of drug resistance.

Authors:  Emily E Evans; Teona Avaliani; Mariam Gujabidze; Tinatin Bakuradze; Maia Kipiani; Shorena Sabanadze; Alison G C Smith; Zaza Avaliani; Jeffrey M Collins; Russell R Kempker
Journal:  PLoS One       Date:  2022-06-24       Impact factor: 3.752

3.  Clinical features associated with linezolid resistance among multidrug resistant tuberculosis patients at a tertiary care hospital in Mumbai, India.

Authors:  J A Tornheim; E Intini; A Gupta; Z F Udwadia
Journal:  J Clin Tuberc Other Mycobact Dis       Date:  2020-07-24

Review 4.  Treatment of Drug-Resistant Tuberculosis.

Authors:  Sundari R Mase; Terence Chorba
Journal:  Clin Chest Med       Date:  2019-12       Impact factor: 2.878

5.  Clinical update on linezolid in the treatment of Gram-positive bacterial infections.

Authors:  Sally Ager; Kate Gould
Journal:  Infect Drug Resist       Date:  2012-06-25       Impact factor: 4.003

6.  Listeria Monocytogenes Meningitis in an Immunocompetent Patient.

Authors:  Oana Magiar; Silvana Vulpie; Corina Musuroi; Iosif Marincu; Alina Murariu; Mirela Turaiche; Silvia Ioana Musuroi; Delia Muntean; Monica Licker
Journal:  Infect Drug Resist       Date:  2022-03-10       Impact factor: 4.003

7.  Linezolid resistance in multidrug-resistant mycobacterium tuberculosis: A systematic review and meta-analysis.

Authors:  Taher Azimi; Saeed Khoshnood; Arezoo Asadi; Mohsen Heidary; Hassan Mahmoudi; Vahab Hassan Kaviar; Masoume Hallajzadeh; Mohammad Javad Nasiri
Journal:  Front Pharmacol       Date:  2022-08-30       Impact factor: 5.988

8.  Clinical outcomes among patients with tuberculous meningitis receiving intensified treatment regimens.

Authors:  A G C Smith; M Gujabidze; T Avaliani; H M Blumberg; J M Collins; S Sabanadze; T Bakuradze; Z Avaliani; R R Kempker; M Kipiani
Journal:  Int J Tuberc Lung Dis       Date:  2021-08-01       Impact factor: 3.427

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.